Xeris Biopharma Holdings (XERS) Return on Sales (2020 - 2026)

Xeris Biopharma Holdings' Return on Sales history runs 7 years deep, the most recent figure standing at 0.0% for Q1 2026.

• Quarterly Return on Sales changed 0.0% year-over-year to 0.0% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.0% (changed 0.0% YoY) and the FY2025 annual result came in at 0.0%, changed 0.0% from the prior year.
• Return on Sales was 0.0% for Q1 2026 at Xeris Biopharma Holdings, down from 0.0% in the prior quarter.
• Across five years, Return on Sales topped out at 0.0% in Q4 2025 and bottomed at 0.02% in Q1 2022.
• A 5-year average of 0.0% and a median of 0.0% in 2023 frame the typical range for Return on Sales.
• Annual changes were most pronounced in 2022 — Return on Sales grew 2 bps — and 2023, when it changed 0 bps.
• Xeris Biopharma Holdings' Return on Sales stood at 0.0% in 2022, then increased by 23 bps to 0.0% in 2023, then soared by 72 bps to 0.0% in 2024, then soared by 252 bps to 0.0% in 2025, then plunged by 79 bps to 0.0% in 2026.
• Business Quant data shows XERS's Return on Sales at 0.0% in Q1 2026, 0.0% in Q4 2025, and 0.0% in Q3 2025.